Overall survival (OS) in metastatic renal cell carcinoma (mRCC) sequentially treated with different targeted therapies (TTs): Results from a large cohort of patients

被引：0
|
作者：
Procopio, Giuseppe
Verzoni, Elena
Iacovelli, Roberto
Testa, Isabella
Salvioni, Roberto
Nicolai, Nicola
Porcu, Luca
De Braud, Filippo G.
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[2] Univ Roma La Sapienza, Oncol Unit, Dept Radiol Oncol & Human Pathol, Rome, Italy
[3] Ist Nazl Tumori, I-20133 Milan, Italy
[4] Mario Negri Inst Pharmacol Res, Milan, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4629
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Outcome of metastatic renal cell carcinoma (mRCC) patients in the era of new targeted therapies
    Ruiz, A. L.
    Bolos, M. V.
    Viqueira, A.
    Esteban, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S654 - S654
  • [22] The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Castro, Daniela
    Tripathi, Nishita
    Sayegh, Nicolas
    Gebrael, Georges
    Li, Xiaochen
    Meza, Luis
    Zengin, Zeynep
    Chehrazi-Raffle, Alex
    Govindarajan, Ameish
    Dizman, Nazli
    Ebrahimi, Hedyeh
    Chawla, Neal
    Mercier, Benjamin
    Hsu, Joann
    Shi, Jessica
    Philip, Errol
    Bergerot, Cristiane
    Barragan-Carrillo, Regina
    Pal, Sumanta
    ONCOLOGIST, 2023, 28 : S5 - +
  • [23] Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies
    Denouel, Angeline
    Heutte, Natacha
    Escudier, Bernard
    Kurtz, Jean-Emmanuel
    Dos Santos, Melanie
    Longato, Nadine
    Desrues, Laurence
    Dauchy, Sarah
    Lange, Marie
    Sevin, Emmanuel
    Rieux, Chantal
    Clarisse, Benedicte
    Castel, Helene
    Noal, Sabien
    Joly, Florence
    CLINICAL GENITOURINARY CANCER, 2018, 16 (05) : 369 - +
  • [24] Prognostic factors for overall survival (OS) in patients with metastatic renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large multicenter study
    Heng, D. Y.
    Xie, W.
    Regan, M. M.
    Cheng, T.
    North, S.
    Knox, J. J.
    Kollmannsberger, C.
    McDermott, D.
    Rini, B. I.
    Choueiri, T. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Association between time to disease progression (TDP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Delea, T.
    Khuu, A.
    Kay, A.
    Zheng, J.
    Baladi, J. F.
    EJC SUPPLEMENTS, 2009, 7 (02): : 430 - 430
  • [26] Brain metastases in patients treated with targeted therapy for metastatic renal cell carcinoma (mRCC)
    Alharbi, H.
    Choueiri, T. K.
    Kollmannsberger, C. K.
    North, S.
    MacKenzie, M. J.
    Knox, J. J.
    Rini, B. I.
    Heng, D. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [27] Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updated results
    Matrana, Marc Ryan
    Duran, Cihan
    Shetty, Aditya
    Xiao, Lianchun
    Atkinson, Bradley J.
    Corn, Paul G.
    Charnsangavej, Chusilp
    Jonasch, Eric
    Tannir, Nizar M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [28] Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.
    Xie, Wanling
    DiNatale, Renzo
    Hakimi, A. Ari
    Donskov, Frede
    Porta, Camillo
    Reaume, M. Neil
    Basappa, Naveen S.
    Hansen, Aaron Richard
    Rini, Brian I.
    Beuselinck, Benoit
    Bjarnason, Georg A.
    Srinivas, Sandy
    Brugarolas, James
    Rha, Sun Young
    Wood, Lori
    Lalani, Aly-Khan A.
    Bosse, Dominick
    Duquette, Audrey
    Heng, Daniel Yick Chin
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [29] Association between treatment effects on disease progression (DP) endpoints and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)
    Delea, T. E.
    Khuu, A.
    Kay, A.
    Zheng, J.
    Baladi, J. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [30] RANDOMIZED, DOUBLE-BLIND PHASE III STUDY OF PAZOPANIB IN PATIENTS WITH ADVANCED/METASTATIC RENAL CELL CARCINOMA (MRCC): FINAL OVERALL SURVIVAL (OS) RESULTS
    Sternberg, C. N.
    Hawkins, R. E.
    Szczylik, C.
    Davis, I. D.
    Wagstaff, J.
    McCann, L.
    Chen, M.
    Rubin, S. D.
    ANNALS OF ONCOLOGY, 2010, 21 : 10 - 10
12345